Novara Biotech reports quarterly revenue above the internal plan
Novara Biotech said demand in its Biotechnology segment held up through the quarter, with management reiterating full-year margin guidance.
Sector Desk
Novara Biotech
Healthcare · Biotechnology
Updated UTC
US$410,77
+5,46+1,35%
After hoursUS$412,82+0,50%
| Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Revenue | 31,67 M | 37,26 M | 41,96 M | 48,31 M | 53,67 M |
| Gross profit | 18,76 M | 21,53 M | 23,9 M | 26,46 M | 32,34 M |
| Operating income | 6,26 M | 7,62 M | 7,85 M | 9,58 M | 11,72 M |
| Net income | 4,88 M | 5,63 M | 6,17 M | 5,78 M | 7,65 M |
Clinical-stage developer of oral therapies for autoimmune and metabolic disorders.
Novara Biotech said demand in its Biotechnology segment held up through the quarter, with management reiterating full-year margin guidance.
Sector Desk
The company approved a multi-year capital program intended to shorten lead times for its largest customers.
Sector Desk
A sell-side desk kept a neutral rating while noting that near-term estimates already reflect steady execution.
Sector Desk
The board named an internal candidate with prior treasury and investor-relations experience to the role.
Sector Desk
The authorization covers a modest slice of the float and will be funded from operating cash flow.
Terminal Brief